CLINICAL STUDY: RISK FACTORS
Optimization of dietary folate or low-dose folic acid supplements lower homocysteine but do not enhance endothelial function in healthy adults, irrespective of the methylenetetrahydrofolate reductase (C677T) genotype
Catherine H. Pullin, BSca,
Pauline A. L. Ashfield-Watt, BAa,
Michael L. Burr, MD, FFPHMa,
Zoë E. Clark, MPhila,
Malcolm J. Lewis, MB, DSc, FESCa,
Stuart J. Moat, PhD ,
Robert G. Newcombe, PhD, C. Stats, MFPHM ,
Hilary J. Powers, PhD ,
Jenny M. Whiting, RGNa and
Ian F. W. McDowell, MD, MRCP, FRCPath*,a
a Cardiovascular Sciences Research Group, Wales Heart Research Institute, Cardiff, United Kingdom
Centre for Human Nutrition, Division of Clinical Sciences, Northern General Hospital, Sheffield, United Kingdom
Department of Medical Computing and Statistics, University of Wales College of Medicine, Heath Park, Cardiff, United Kingdom
Manuscript received December 6, 2000;
revised manuscript received August 15, 2001,
accepted August 29, 2001.
* Reprint requests and correspondence: Dr. Ian F. W. McDowell, Department of Medical Biochemistry, University of Wales College of Medicine, Heath Park, Cardiff, CF14 4XN, Wales United Kingdom mcdowell{at}cardiff.ac.uk
OBJECTIVES
We sought to study the effect of low-dose folic acid supplementation or optimization of dietary folate intake on plasma homocysteine and endothelial function in healthy adults.
BACKGROUND
Elevated homocysteine is associated with cardiovascular disease, but it is not known whether this relationship is causal. Individuals homozygous (TT) for the C677T mutation in the methylenetetrahydrofolate reductase (MTHFR) gene ( 12% of the population) have increased homocysteine levels, particularly in association with suboptimal folate intake.
METHODS
Healthy subjects (n = 126; 42 of each MTHFR genotype) were included in this cross-over study of three interventions of four months each: 1) placebo plus natural diet; 2) daily 400-µg folic acid supplement plus natural diet; and 3) increased dietary folate intake to 400 µg/day.
RESULTS
At baseline, homocysteine was inversely related to plasma folate and was higher in TT homozygotes. For the whole group, plasma folate increased by 46% after dietary folate and by 79% after supplementation, with reductions of homocysteine of 14% and 16%, respectively. Within the genotype, TT homozygotes exhibited the most marked changes in these variables. Brachial artery endothelial function, as determined by a change in end-diastolic diameter in response to increased flow, was not changed by increased folate intake (98 ± 73 µm at baseline, 110 ± 69 µm after a high-folate diet, 114 ± 59 µm after supplementation and 118 ± 68 µm after placebo). Plasma von Willebrand factor antigen was unaltered.
CONCLUSIONS
Optimization of dietary folate or low-dose folic acid supplementation reduces plasma homocysteine but does not enhance endothelial function, irrespective of the MTHFR (C667T) genotype.
|
Abbreviations and Acronyms
| | ANOVA | = analysis of variance | | FMD | = flow-mediated dilation | | MTHFR | = methylenetetrahydrofolate reductase | | NO | = nitric oxide | | vWF(Ag) | = von Willebrand factor (antigen) |
|
This article has been cited by other articles:

|
 |

|
 |
 
A. de Bree, L. A van Mierlo, and R. Draijer
Folic acid improves vascular reactivity in humans: a meta-analysis of randomized controlled trials
Am. J. Clinical Nutrition,
September 1, 2007;
86(3):
610 - 617.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
C. J. Abularrage, A. N. Sidawy, P. W. White, G. Aidinian, K. J. DeZee, J. M. Weiswasser, and S. Arora
Effect of Folic Acid and Vitamins B6 and B12 on Microcirculatory Vasoreactivity in Patients With Hyperhomocysteinemia
Vascular and Endovascular Surgery,
September 1, 2007;
41(4):
339 - 345.
[Abstract]
[PDF]
|
 |
|

|
 |

|
 |
 
C. Shirodaria, C. Antoniades, J. Lee, C. E. Jackson, M. D. Robson, J. M. Francis, S. J. Moat, C. Ratnatunga, R. Pillai, H. Refsum, et al.
Global Improvement of Vascular Function and Redox State With Low-Dose Folic Acid: Implications for Folate Therapy in Patients With Coronary Artery Disease
Circulation,
May 1, 2007;
115(17):
2262 - 2270.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. J.M. de Craen, D. J. Stott, R. G.J. Westendorp, A. Khare, M. Lopez, J. Gogtay, E. P. Quinlivan, J. F. Gregory III, H. Refsum, A. D. Smith, et al.
Homocysteine, B vitamins, and cardiovascular disease.
N. Engl. J. Med.,
July 13, 2006;
355(2):
205 - 206.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
K. E. MacKenzie, E. J. Wiltshire, R. Gent, C. Hirte, L. Piotto, and J. J. Couper
Folate and Vitamin B6 Rapidly Normalize Endothelial Dysfunction In Children With Type 1 Diabetes Mellitus
Pediatrics,
July 1, 2006;
118(1):
242 - 253.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. J. Moat, S. N. Doshi, D. Lang, I. F. W. McDowell, M. J. Lewis, and J. Goodfellow
Treatment of coronary heart disease with folic acid: is there a future?
Am J Physiol Heart Circ Physiol,
July 1, 2004;
287(1):
H1 - H7.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. Little, L. Sharp, S. Duthie, and S. Narayanan
Colon Cancer and Genetic Variation in Folate Metabolism: The Clinical Bottom Line
J. Nutr.,
November 1, 2003;
133(11):
3758S - 3766.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. J. Moat, P. A.L. Ashfield-Watt, H. J. Powers, R. G. Newcombe, and I. F.W. McDowell
Effect of Riboflavin Status on the Homocysteine-lowering Effect of Folate in Relation to the MTHFR (C677T) Genotype
Clin. Chem.,
February 1, 2003;
49(2):
295 - 302.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
N. Weiss, C. Keller, U. Hoffmann, and J. Loscalzo
Endothelial dysfunction and atherothrombosis in mild hyperhomocysteinemia
Vascular Medicine,
August 1, 2002;
7(3):
227 - 239.
[Abstract]
[PDF]
|
 |
|
|